Shares of Viveve Medical, Inc. (NASDAQ:VIVE) have been given an average rating of “Buy” by the six research firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $10.40.
Several research firms recently weighed in on VIVE. Mizuho began coverage on shares of Viveve Medical in a report on Thursday. They issued a “buy” rating and a $10.00 price objective for the company. Maxim Group reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Viveve Medical in a report on Friday, August 11th. Cowen and Company reiterated a “buy” rating and issued a $11.00 price target on shares of Viveve Medical in a research report on Thursday, August 17th. Finally, ValuEngine upgraded shares of Viveve Medical from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.
In other Viveve Medical news, CFO Scott Durbin purchased 5,000 shares of the company’s stock in a transaction on Wednesday, August 23rd. The shares were purchased at an average cost of $5.25 per share, for a total transaction of $26,250.00. Following the completion of the transaction, the chief financial officer now owns 11,568 shares in the company, valued at $60,732. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 35.10% of the stock is currently owned by insiders.
Institutional investors have recently modified their holdings of the business. ING Groep NV bought a new stake in Viveve Medical in the second quarter worth about $1,205,000. Numeric Investors LLC acquired a new stake in Viveve Medical during the 2nd quarter worth about $330,000. Bank of New York Mellon Corp acquired a new stake in Viveve Medical during the 2nd quarter worth about $310,000. Manatuck Hill Partners LLC raised its holdings in Viveve Medical by 128.6% during the 2nd quarter. Manatuck Hill Partners LLC now owns 400,000 shares of the company’s stock worth $2,872,000 after buying an additional 225,000 shares during the period. Finally, HighTower Advisors LLC raised its holdings in Viveve Medical by 33.2% during the 2nd quarter. HighTower Advisors LLC now owns 1,723,751 shares of the company’s stock worth $12,379,000 after buying an additional 430,033 shares during the period. Hedge funds and other institutional investors own 65.92% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Analysts Set Viveve Medical, Inc. (VIVE) PT at $10.50” was published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://transcriptdaily.com/2017/11/20/analysts-set-viveve-medical-inc-vive-pt-at-10-50.html.
Viveve Medical (VIVE) traded up $0.17 during mid-day trading on Thursday, reaching $4.98. 119,334 shares of the company traded hands, compared to its average volume of 207,387. Viveve Medical has a 1-year low of $3.75 and a 1-year high of $11.16. The company has a debt-to-equity ratio of 2.72, a current ratio of 3.89 and a quick ratio of 3.63.
Viveve Medical (NASDAQ:VIVE) last posted its quarterly earnings data on Wednesday, November 8th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.08). The company had revenue of $4.07 million during the quarter, compared to analyst estimates of $4.10 million. Viveve Medical had a negative return on equity of 275.77% and a negative net margin of 257.58%. The business’s revenue for the quarter was up 120.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.46) EPS. analysts anticipate that Viveve Medical will post -2 EPS for the current fiscal year.
About Viveve Medical
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
Receive News & Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.